Acute lymphoblastic leukemia (ALL) is a heterogeneous group of hematologic malignancies
characterized by abnormal proliferation of immature lymphoid cells. It is the most commonly …

Transcription factor IKZF1 (IKAROS) acts as a critical regulator of lymphoid differentiation
and is frequently deleted or mutated in B-cell precursor acute lymphoblastic leukemia. IKZF1 …

Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy.
Advancements in technology that enhance our understanding of the biology of the disease …

ENCODE comprises thousands of functional genomics datasets, and the encyclopedia
covers hundreds of cell types, providing a universal annotation for genome interpretation …

Improved personalized adjustment of primary therapy to the perceived risk of relapse by
using new prognostic markers for treatment stratification may be beneficial to patients with …

PURPOSE The ALL10 protocol improved outcomes for children with ALL by stratifying and
adapting therapy into three minimal residual disease–defined risk groups: standard risk …

Novel biological subtypes and clinically important genetic aberrations (druggable lesions,
prognostic factors) have been described in B-other acute lymphoblastic leukemia (ALL) …

Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy, and
implementation of risk-adapted therapy has been instrumental in the dramatic improvements …

The biological regulation of transcription factors (TFs) and repressor proteins is an important
mechanism for maintaining cell homeostasis. In B cell acute lymphoblastic leukemia (B-ALL) …

Acute lymphoblastic leukaemia (ALL) occurs in approximately 1: 1500 children and is less
frequently found in adults. The most common immunophenotype of ALL is the B cell lineage …